Eric Lander talks CRISPR and the infamous Nobel ‘rule of three’
By Joel Achenbach,
The Washington Post
| 04. 21. 2016
Untitled Document
“Funny tensions in science.” That’s a phrase from the lips of Eric Lander, president and founding director of the Broad Institute of MIT and Harvard.
He was in Washington earlier this week to appear at the Aspen Institute in conversation with journalist/biographer Walter Isaacson, and inevitably the talk turned to CRISPR, the revolutionary gene-editing technique, and to Lander’s controversial essay earlier this year in the journal Cell, “The Heroes of CRISPR.” The scientific community's reaction highlighted the aforementioned funny tensions; as my colleague Carolyn Johnson reported, Lander's review of the history of CRISPR set off an epic social-media kerfuffle.
In the essay, Lander distributed credit widely for the CRISPR discovery – which rankled some parties who thought they deserved more attention, or felt that Lander had overemphasized the contribution of one of his Broad Institute colleagues. He described CRISPR as the result of many converging innovations, rather than as something that erupted in a classic Eureka! moment. (In this sense, CRISPR is like the computer; as my friend Walter's book "The Innovators" points out, no single person...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...